3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Emily Keeton of Loeb.nyc, Steve Kean of GHP, and Lacey Tezino of Passport Journeys. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from investing to mental health — recently making headlines in Houston innovation.

Emily Keeton, operating partner and investor of Loeb.nyc

Emily Keeton has worn a lot of hats in Houston's innovation ecosystem and beyond. She shares on the Houston Innovators Podcast how she's engaging with companies these days, what the future holds for Houston, and more. Photo courtesy

Emily Keeton has had a front-row seat as the Houston innovation ecosystem developed — first hands on as a co-founder of Station Houston, and later from outside looking in from New York. As she shared on the Houston Innovators Podcast, she's hopeful about the future of the community.

"I am very optimistic about the future of Houston. It's a long game, and I think people need to keep showing up," she says on the show.

Now based in Houston, her latest endeavor is working with Michael Loeb on Loeb.nyc, a New York-based investment firm with shared services — marketing, design, etc. — with his portfolio. Read more.

Steve Kean, incoming president and CEO of the Greater Houston Partnership

Steve Kean will transition from leading Kinder Morgan to assuming the role of president and CEO of the Greater Houston Partnership later this year. Photo courtesy of the GHP

Steve Kean, who currently serves as the CEO of Kinder Morgan Inc., has been announced as the next president and CEO of the Greater Houston Partnership. He's expected to transition from CEO to board of directors member at Kinder Morgan on August 1. Kean will then assume his new position at GHP no later than Dec. 1.

“I’m grateful for the opportunity to serve our region in this role," he says. "I look forward to building on what Bob, the Board, members, and staff of the Partnership have accomplished. I know first-hand the opportunities that a vibrant business sector can create for people and communities. I look forward to expanding those opportunities further.”

The GHP's outgoing president and CEO, Bob Harvey, announced his retirement earlier this year, and will remain in his position until Kean is onboarded. Read more.

A Houston-founded company is targeting mothers and daughters with their teletherapy app. Photo courtesy of Passport Journeys

When Lacey Tezino’s mother died of cancer she vowed to help other mothers and daughters find their own ways to bond in beautiful, nurturing ways. She turned that vow into a mission that is now available for others to embark on with an online therapy app tailored specifically for the mother-daughter dynamic Passport Journeys.

The app, which launched aptly on Mother's Day, can be downloaded via Apple or Google Play, and includes video therapy sessions, journal opportunities, interactive worksheets, and help those who need access to this form of mental health help with ease.

“Outside of our target audience being mother-daughter, we are also the first teletherapy app to find prescribed activities,“ Tezino tells InnovationMap. “We are the first ones that are actually having the therapist in between their video sessions assign the mother-daughter pair intentional bonding activities. It is meant for them to spend quality time on where they are at in their relationship…there aren’t any other apps that are doing that.” Read more.

From Your Site Articles
Emily Keeton has worn a lot of hats in Houston's innovation ecosystem and beyond. She shares on the Houston Innovators Podcast how she's engaging with companies these days, what the future holds for Houston, and more. Photo courtesy

Long-time innovator shares why she's optimistic about Houston's future as a hub for startups, tech

HOUSTON INNOVATORS PODCAST EPISODE 191

As she describes, Emily Keeton's strength and her curse is that she lacks patience. For this reason, her career, launched originally in investment banking, has taken her from the startup world to media and beyond.

"I'm a person of action, and I think that works well when you work with a startup. You tend to get things done," Keeton says on the Houston Innovators Podcast, adding that she's been called a change agent, and while the terminology isn't her preference, she agrees its an accurate identifier for her. "I can step into a situation, and, after many years of working with so many different companies, I have a lens of pattern recognition of what's worked in the past and potential footfalls. It's what keeps me coming back to startups."

Keeton was one of the founding members of Station Houston — along with John "J.R." Reale, Grace Rodriguez, Blair Garrou, and some other innovators who played a central role in the organization almost a decade ago. The goal was to create a community where startup founders in Houston can go for support from mentors and peers. The organization rolled into into a few entities like the Ion and Capital Factory in 2018.

After her role at Station, Keeton's career took her back to New York, where she worked with WeWork, Mercado, Tempest, and other consumer-facing businesses. She always had one foot still in Houston, until she recently relocated to Houston entirely. She served as COO of Houston Landing, a new nonprofit journalism platform, and her latest endeavor is working with Michael Loeb on Loeb.nyc, a New York-based investment firm with shared services — marketing, design, etc. — with his portfolio.

"I'm based here, and I'll be doing a couple of things, working with a few of the portfolio companies," she says. "And I'm on the lookout for early stage companies here in Texas."

Keeton's perspective, having seen the Houston innovation ecosystem develop — first hands on in Houston, and later from outside looking in from New York — is hopeful. She says that with Station, they realized the power of mentorship — specifically of mentors who have led a startup through scale and exit. Now, Houston just needs more exits and success stories to grow that mentorship base.

"I am very optimistic about the future of Houston. It's a long game, and I think people need to keep showing up," she says on the show.

She adds that what's happening right now is a winter for startups, and she notes that this isn't just something seen in Houston. But this period of time can be an advantage to innovators.

"It's a great time to launch a company," Keeton says, explaining that a few years ago, checks were being written without significant due diligence. Now, this pace has slowed. "It provides a bit of breathing room for people to figure out their business model."

Keeton shares more on her observations of Houston's tech and startup scene and what she looks for in the startups she invests her time and money in on the show. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings